



MINI WELL PROXA

PRODUCT TECHNICAL SHEET

MINI WELL PROXA

1. Trade Name

MINI WELL PROXA is a kit composed by an acrylic aspherical intraocular lens (CE0426) and a dedicated injection system (CE0482)

MINI WELL PROXA Series Code: 1121CCZ

Individual product code:

MINI WELL PROXA: 1121CCZPXXXXA (dioptric range $+30.0D \div 0.0 D$)

Where:

P = positive dioptric power

XXXX = dioptric power between 00.00 and 30.00

2. EMDN

IOL: P030102100202

INJECTOR: Q0299

3. Manufacturer

IOL: SIFI S.p.A.

Via Ercole Patti, 36

95025 - Aci S. Antonio (CT) – Italy

INJECTOR: Medice AG

Dornierstrasse 11

CH-9423 Altenrhein – Switzerland

4. EC Marking

IOL: CE 0426

INJECTOR: CE 0482

5. Compliance

Regulation EU 745-2017 of the European Parliament and of the council of 5 april 2017 on medical devices

UNI CEI EN ISO 13485:2021 Medical Devices, Quality Management Systems - Requirements for

Regulatory Purposes

UNI EN ISO 9001:2015+A1:2024 Quality System - Requirements

6. European Classification

IIb

7. General Product Description

MINI WELL PROXA is a progressive extended depth of focus intraocular lens intended to be implanted in the posterior chamber, more precisely in the capsular bag, to replace the natural crystalline lens for surgical correction of aphakia and presbyopia in adult patients.



MINI WELL PROXA

PRODUCT TECHNICAL SHEET

MINI WELL PROXA is pre-loaded, comes in a single-piece design and is intended for mini incision. This surgical implant is made of a hydrophilic-hydrophobic copolymer with a UV-filtering chromophore and a refractive index of 1.46 at 35°C. The anterior surface of MINI WELL PROXA IOL is based on a patented proprietary optics that provides an extended depth of focus for progressive vision at all distances, with an improved lens focusing capability starting at 35 cm. The anterior surface of MINI WELL PROXA is aspheric. The posterior surface has a double square edge which is intended to reduce the incidence of posterior capsule opacification. MINI WELL PROXA has a biconvex optical shape for the entire dioptric range. This surgical medical device is a system consisting of an intraocular lens and a disposable injector pursuant to Regulation (EU) 745-2017.

Physical characteristics:

Water content	25%	
Refraction index	at 35°C (in hydrated status)	1.46

Range of dioptric powers:

Lens model	Min. Power (D)	Max. Power (D)	Incremental Step (D)	Incremental step (D)
MINI WELL PROXA	0.0	+30.0	0.5 from +10.5 to + 30.0	1.0 from 0.0 to +10.0

Technical characteristics:

Lens model	Diameter of the optical plate (mm) $\varnothing_p$	Total diameter (mm) $\varnothing_T$	N° of loops	Vaulting	Corneal Equivalent additional (D)
MINI WELL PROXA	6.0	10.75	4	5°	+3.25

Lens model, spherical dioptric power, suggested A constant and main dimensions (diameter of the optical plate, total diameter, vaulting) are reported on the case and the primary and secondary packaging.

8.Composition/Device Material/Technical Characteristics

MINI WELL PROXA intraocular lens models are made of a hydrophilic – hydrophobic copolymer constituted by 2-HEMA (2-hydroxyethyl methacrylate) and EOEMA (2-ethoxyethyl methacrylate) with a chromophore that filters ultraviolet radiation and a refractive index 1.46 at 35°C.

Component 2-HEMA is a hydrophilic monomer, while component EOEMA is a hydrophobic monomer. The two combined monomers form an acrylic polymer that compared to the individual monomers has a higher refractive index and better mechanical properties.

Furthermore, the polymer is ultrapure, i.e. without any residual acid, with zero ionicity thus excluding any possibility that the lens might become opaque due to calcium deposits.

9.Indications

The MINI WELL PROXA intraocular lens is intended for primary implantation for visual correction of aphakia in adult patients (> 18 years old) with or without presbyopia after removal of a cataractous lens and aphakia after refractive lensectomy in presbyopic adults who desire increased spectacle independence for distance and near vision. This implant must be positioned within the capsular bag.



MINI WELL PROXA

PRODUCT TECHNICAL SHEET

10. Combined use of MINI WELL and MINI WELL PROXA

MINI WELL and MINI WELL PROXA intraocular lenses have been designed to be used also in combined bilateral implant condition.

The combined implant of MINI WELL and MINI WELL PROXA allows to obtain a unique system based on the complementary optical design of the two lens models.

11. Instructions for use

1. Appropriate implant selection

- a. Examine the label of the complete package to verify the model, dioptric power or spherical equivalent, design and date of expiration of the product.
- b. Suggested constant A: the constant A on the package is intended as a guideline and starting point for calculating the dioptric power of the implant. We suggest that surgeons should develop the constant value based on their clinical experience.

2. Removing the implant from its package

- a. After opening the case, check that the information on it corresponds to that listed on the label in the lens package.
- b. Open the lens external package and transfer the lens container in the sterile field in accordance with good practices in sterile field management.
- c. Open the injector blister and place it on the sterile operating table.
- d. Carefully open the lens container and remove the loading chamber in which it is lodged.
- e. Insert the loading chamber holding the IOL into the specific injector slot.
- f. Apply viscoelastic solution first through the front hole until the tip is filled and then through the rear hole towards the back of the chamber until the solution comes out, in order to obtain a barrier between lens and silicone cushion.
- g. In addition, apply a drop of viscoelastic solution on the tip of the silicone cushion. It is recommended to use the SIFI viscoelastic solution, in order to allow the correct lens injection procedure.
- h. Carefully remove the loading chamber block by lifting it from below with thumb finger and holding the upper part with index and middle fingers. Check that the lens is located at the centre of the loading chamber. Close the cartridge sides together until the "click-lock" mechanism engages.
- i. Push forward the plunger softly and ensure that the silicone cushion correctly enters the loading chamber. Continue to push the plunger bringing the lens toward the tip of the injector. In the event the lens-injector system gets jammed, stop using the device.

3. Lens Injection

- a. Introduce the injector tip, with the sloping side facing down and inject the intraocular lens into the bag.
- b. After the injection, pull out the injector from the incision.
Attention: When the loading chamber is introduced into the injector, the plunger should be in the pulled-back position. The injector tip must be handled with care, especially during insertion of the loading charge into the injector. It must not be damaged in order not to jeopardize the injection operation.

12. Sterilization

The intraocular lens package consists of a double-barrier steam-sterilized assembly; the injector and the blister in which it is lodged are sterilized with ethylene oxide.

Steam sterilization is compliant with standard UNI EN ISO 17665-1.

13. Packaging

MINI WELL PROXA intraocular lens is supplied in a hydrated state. The package consists of a double sterile barrier film.



MINI WELL PROXA

PRODUCT TECHNICAL SHEET

The primary package of this IOL consists of a plastic container sealed by an aluminum foil containing a specific loading chamber where the IOL is inserted. The plastic container is filled with a sterile and apyrogenic saline solution. The plastic container is packaged in turn in a pouch.

The primary package of the injector consists of a Tyvek blister.

The case representing the SKU contains the lens and its injector, the "Product Information" leaflet, the implant card and the labels with the lens ID information.

14. Warnings

1. Patients with one or more of the following conditions are not eligible candidates for implantation of a progressive intraocular lens, as it can worsen the pre-existing condition, interfere with diagnosis or the treatment of a condition or potentially be a risk for the patient's sight:
 - a) zonula laxity
 - b) irregularities and decentralisation of the capsulorhexis
 - c) recurrent inflammation of anterior or posterior segment of unknown etiology (chronic Uveitis)
 - d) patients in whom the intraocular lens can interfere with the ability to observe, diagnose or treat posterior segment conditions
 - e) intraoperative challenges which could increase the risk of complications, such as severe bleeding, significant iris damage, uncontrollable elevated intraocular pressure or significant vitreous loss
 - f) lack of capsular support for implantation of the intraocular lens in the capsular bag
 - g) decompensated glaucoma
 - h) dystrophy of corneal endothelium
 - i) proliferative diabetic retinopathy
 - j) microphthalmus
 - k) paediatric patients
 - l) suspected microbial infection
 - m) patients without an adequate support for the lens from the posterior chamber or the zonule
 - n) bilateral congenital cataract
 - o) history of retinal detachment or susceptibility to this condition
 - p) monocular patients
2. MINI WELL PROXA IOL must be positioned within the capsular bag and not in the ciliary sulcus.
3. Carefully remove all viscoelastic material from the capsular bag. Residues not removed could lead to IOL opacification and increase in intraocular pressure.
4. Choice of type of IOL to be used as well as the implantation method to be adopted (monolateral, bilateral or combined) must be evaluated case by case by the physician according to the clinical need of the patient.
5. Other potential complications following IOL implantation are correlated to cataract surgery..

15. Precautions for use

1. In patients who have undergone implantation of the MINI WELL PROXA intraocular lens, the auto-refractometer values may not correspond to the actual post-operative refractive value; it is therefore advisable to check the aforementioned values with the subjective examination, through the "fogging" technique.
2. The recent use of contact lenses affects the patient's refraction; therefore, in those wearing contact lenses, surgeons must define corneal stability without contact lenses before determining the power of the intraocular lens.
3. Do not re-sterilise the intraocular lens.
4. Do not reuse the intraocular lenses; reuse compromises the sterility of the implant.
5. Do not use the system if the package is damaged or open.
6. Do not use after the expiration date printed on the package.
7. Do not use balanced saline solutions, Ringer lactate and/or hydroxypropyl methylcellulose during the loading procedures of the lens into the injector.



MINI WELL PROXA

PRODUCT TECHNICAL SHEET

8. Improper handling of the preloaded system, as well as improper bending techniques may cause damage to the haptics and / or the optical part of the lens. The surgeon must not attempt to implant lenses with a damaged optical plane or haptics. For a correct handling of the medical device follow the instructions for use being provided.
9. The intraocular lens implant requires adequate surgical skills.
10. Opening the protective packaging requires immediate use of the intraocular lens to prevent contamination or dehydration.
11. MINI WELL PROXA intraocular lens must be kept at room temperature. It is recommended to implant them after keeping them at least 60 minutes at the temperature of the operating room. In this way it is possible to avoid that the thermal shock, resulting from an abrupt exposure to body temperature, causes a transient loss of transparency of the device.
12. MINI WELL PROXA must be implanted exclusively with the injector Accuject Pro 1.8-1P included in the package (Incision size: Wound-assisted technique: 1.8 mm; Into-the-wound technique: 2.0 mm; Into-the-bag technique: 2.2 mm).

16. Adverse events

The potential adverse events that may occur during or after cataract surgery with implantation of an intraocular lens may include but are not limited to:

General adverse events for intraocular lenses

1. Residual refractive error
2. Increase of intraocular pressure
3. Corneal edema
4. Inflammation (Endophthalmitis, Hypopyon, Cystoid macular oedema)
5. Pupillary block
6. Retinal detachment
7. Displacement of the intraocular lens (Tilt and decentralisation)
8. Secondary surgical intervention (including repositioning of the implant, removal and replacement, PCO, or other surgical procedure)
9. Any other adverse event that leads to permanent damage to eyesight or requires surgery or a doctor to avoid this epilogue.

Adverse events for MINI WELL PROXA intraocular lens

Increased visual disorders related to the optical characteristics of the intraocular lens:

- a. Reduction of contrast sensitivity
- b. Light artifacts (halos, glare or *starbursts*)

17. Safety Information

MINI WELL PROXA intraocular lenses do not contain latex or phthalates.

18. Compatibility with other products

There are no interactions between the intraocular lens and other devices or therapies.

19. Validity

4 years.



MINI WELL PROXA

PRODUCT TECHNICAL SHEET

20. Storage and Handling Conditions

Store at temperatures between $+5^{\circ}\text{C}$ – $+25^{\circ}\text{C}$. If the lenses are exposed to temperatures other than those shown in the case, it is recommended to stabilize them at the operating room temperature at least 60 minutes before the implant.

During transport, non-prolonged exposure of the product to temperatures higher than those suggested for the storage (up to a maximum of $+45^{\circ}\text{C}$) does not compromise the characteristics of the product.

21. Disposal

MINI WELL PROXA are aspheric IOLs intended to be implanted in the posterior chamber of the eye, more precisely in the capsular bag. In case of disposal, the abovementioned medical devices must be considered as medical waste and disposed of as such (according to applicable national requirements).

The injector provided may be contaminated with potentially infectious substances of human origin after use.

Dispose of the injector after use according to the applicable guidelines of biological hazardous waste.

END OF DOCUMENT

Rev. 00 of 01/10/2024